News and Announcements
Walker Capital announce January performance with High Growth Strategy as best performing
- Published February 01, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
The overall market started off with an interesting event for 2019 with a flash crash of the forex market which happened in the quietest time of the day, Apple also issued a downgrade of revenue of 10% and the Yen was near extreme levels which added to this movement.
Walker Capital were not overexposed to the market at this time. These events caused a small loss on a couple of strategies and the high growth Strategy is positive and off to a great start for the year.
January Performance:
Swing Strategy – Annualised rate of Return -1.68%
Multi Strategy – Annualised rate of Return -3.65%.
Growth Strategy – Annualised rate of Return -11.47%.
High Growth Strategy – Annualised rate of Return 18.79%.
About Walker Capital
Walker Capital is to raise up to $900,000 for 20% in equity. The capital will be used to fund the expansion of the Company as it increases its marketing campaign aimed at expanding its client base and developing an investment platform for its clients.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
